期刊文献+

依托考昔与秋水仙碱缓解痛风急性发作的疗效对照研究 被引量:3

A Comparative Study on the Efficacy of Etoricoxib and Colchicine in Relieving Acute Attack of Gout
下载PDF
导出
摘要 目的:比较依托考昔和秋水仙碱治疗痛风急性发作的临床疗效。方法:选取某院2017年6月~2019年6月收纳的急性痛风患者160例,采用随机数表法将其分为A组与B组各80例,A组患者进行依托考昔治疗,B组患者利用秋水仙碱治疗,比较两组临床疗效、治疗前后的疼痛指数和治疗期间不良反应发生率。结果:A组患者临床疗效总有效率为96.25%,B组患者总有效率为95.00%,两组患者临床疗效总有效率经比较差异无统计学意义(P>0.05);两组患者治疗前后VAS评分经比较均无统计学意义(P>0.05),治疗后两组患者疼痛指数均显著下降低于治疗前;A组患者不良反应发生率为1.25%,B组患者不良反应发生率为5.00%,B组患者不良反应发生率要比A组患者稍高一些,差异无统计学意义(P>0.05)。结论:依托考昔和秋水仙碱治疗痛风急性发作均有显著疗效,能够有效改善患者病情,但依托考昔对患者机体影响较小,安全性更高,不会对患者胃肠道造成较大影响。 Objective:To compare the clinical effect of etoricoxib and colchicine in relieving acute attack of gout.Methods:A total of 160 patients with acute gout admitted to a hospital from June 2017 to June 2019 were selected and divided into group A and group B by random number table method,with 80 cases in each group.The group A were treated with etoricoxib,and group B was treated with colchicine,then the clinical efficacy,pain index before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate was 96.25%in group A and 95.00%in group B.There was no statistically significant difference between the two groups(P>0.05).There was no significant difference in VAS scores between the two groups before and after treatment(P>0.05).The pain indexes of the two groups after treatment were significantly lower than that before treatment.The incidence of adverse reactions was 1.25%in group A and 5.00%in group B.The incidence of adverse reactions in group B was slightly higher than that in group A,and the difference was not statistically significant(P>0.05).Conclusion:Both etoricoxib and colchicine have significant curative effect in the treatment of acute gout attack,which can effectively improve the patient's condition,but the effect of etoricoxib on the patient's body is small,the safety is higher,and it will not have a great effect on the gastrointestinal tract of the patients.
作者 斯璐露 朱小春 Si Lulu;Zhu Xiaochun(Wenzhou Medical University,Wenzhou 325035;No.1 Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035)
出处 《数理医药学杂志》 2021年第1期81-83,共3页 Journal of Mathematical Medicine
关键词 依托考昔 秋水仙碱 急性痛风 临床疗效 etoricoxib colchicine acute gout clinical efficacy
  • 相关文献

参考文献7

二级参考文献38

  • 1方卫纲,曾学军,李梦涛,Lan X Chen,H Ralph Schumacher Jr,张奉春.关于痛风诊治决策的调查及相关因素分析[J].中华医学杂志,2006,86(27):1901-1905. 被引量:9
  • 2菲尔斯坦.凯利风湿病学[M].7版.北京:人民卫生出版社,2006:1199-1216. 被引量:1
  • 3Ioannis M, Konstantinos K, Konstantinos R. Neutrophils, IL-113, and gout: is there alink[J]. Semin Immunopathol, 2013, 35: 501-512. 被引量:1
  • 4Liu BR, Peter S, Anya S, et al. Innate Immunity Conferred by Toll-like Receptors 2 and 4 and Myeloid Differentiation Factor 88 Expression Is Pivotal to Monosodium Urate Monohydrate Crystal- Induced Inflammation[J]. Arthritis Rheum, 2005, 52(9) : 2936-2946. 被引量:1
  • 5Yan C, Yi HP, Zhong T. Association of Toll-like receptor 2 polymorphisms with gout[J]. Biomedical Reports, 2014, 2: 292-296. 被引量:1
  • 6Coderre TJ, Wall PD. Ankle joint urate arthritis in rats: An ahernative animal modle of arthritis to that produce by Freud's adjuvant[J]. Pain, 1987, 28(3): 379-393. 被引量:1
  • 7Landis RC, Yagnik DR, Florey O, et al. Safe disposal of inflammatory monosodium urale monohydrate crystals by differentiated macrophages[J]. Arthritis Rheum, 2002, 46: 3026-3033. 被引量:1
  • 8William JM, Jacquie LH. Innate inflammation and resolution in acntegout[J]. Immunology and Cell Biology, 2010, 88: 15-19. 被引量:1
  • 9Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body[J]. Annu Rev Immunol, 2009, 27: 229-265. 被引量:1
  • 10Triantafilou M, Gamper FG, Haston RM, et al. Membrane sorting of toll-like receptor (TLR) 2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting[J]. J Biol Chem, 2006, 281(41) : 31002-31011. 被引量:1

共引文献184

同被引文献38

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部